Phase 1 N=24 Bioequivalence of IMP 08P1902F0 Relative to Contramal® (100 mg/mL Oral Solution)
Healthy
Primary: Cmax of Tramadol Hydrochloride for the Test and the Reference Products — 139.65; 123.90 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=171 AMG 404 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=33 Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 3; 3; 3; 3 Participants
Phase 1 N=32 Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)
Acute Pain
Primary: Paracetamol Peak Plasma Concentration (Cmax) After Single Dose — 2181.04 ng/mL
Phase 1 N=11 Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test
Metabolic Diseases
Primary: Oral Glucose Sensitivity Index (Kisspeptin-Placebo) — 517; 521 ml min-1m-2
Phase 1 N=6 Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Number of Participants With Treatment-related Adverse Events Occurring During the Enrollment Period as Assessed by the Investigator Using the CTCAE 4.0 Scale. — 2; 0…
Phase 1 N=44 Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers
COVID-19
Primary: Number of Participants With at Least One Solicited Local Adverse Event (AE) Within 8 Days After the Injection of Prime Dose — 8; 6; 10; 10 Participants
Phase 1 N=16 Safety of Intravenous Apramycin in Adults
Bacterial Infection
Primary: Area Under the Concentration-time Curve From Time Zero to 8 h (AUC 0-8) of Total Apramycin in Epithelial Lining Fluid (ELF) and Alveolar Macrophage (AM) — 142.8; 131.7…
Phase 1 N=27 Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Solid Tumors · Lymphoma
Primary: Dose Escalation Phase: Maximum Tolerated Dose (MTD) of LMP744 (NSC 706744) — 190 mg/m^2
Phase 1 N=84 A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
Tuberculosis · Tuberculosis, Pulmonary
Primary: Number of Participants With Treatment-related Adverse Events — 0; 1; 1; 0 Participants
Phase 1 N=52 BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Metastatic or Locally-advanced Unresectable Breast Cancer
Primary: Phase II Dose of BYL719/Alpelisib (Arm A and Arm B) — 250; 250 mg
Phase 1 N=55 A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Carcinoma, Hepatocellular · Biliary Tract Cancer · Secondary Liver Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 0; 2 Participants
Phase 1 N=100 A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience
Healthy Volunteers
Primary: Treatment Phase: Drug Liking (Maximum Effect [Emax]) "At This Moment" as Assessed Using Bipolar Visual Analogue Scale (VAS) — 56.7; 57.3; 56.5; 88.5 score on a scale
Phase 1 N=43 A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.
Healthy
Primary: Placebo-Adjusted Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) at Expected Maximum Concentration (Cmax) on Day 3 for Sisunatovir…
Phase 1 N=4 Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
Tuberculosis · Tuberculosis, Pulmonary · Bacterial Infections Respiratory
Primary: Rates and Routes of Excretion — 331; 162 mg eq